SII logo
SII logo
news

NEWS

Serum - Protection from birth onwards

Serum News

16 September, 2021

Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance

Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute of India Pvt. Ltd. today announced a strategic alliance. Read more...

Serum News

17 August, 2021

SCHOTT and Serum Institute of India Announce Joint Venture for Pharmaceutical Packaging

Serum Institute of India (SII) acquires 50% stake of SCHOTT Kaisha to become SCHOTT’s joint venture partner and secure pharma packaging supply. Read more...

Serum News

13 August, 2021

Dr. Cyrus S. Poonawalla receives Lokmanya Tilak National Award 2021

Dr. Cyrus Poonawalla was conferred with the prestigious Lokmanya Tilak National Award 2021 by Lokmanya Tilak Smarak Trust in Pune. Read more...

Serum News

06 August, 2021

Novavax and Serum Institute of India Announce Submission to Regulatory Agencies

Novavax and Serum Institute of India file regulatory submissions to the Drugs Controller General of India and to regulatory agencies in Indonesia and Philippines for Novavax' recombinant nanoparticle COVID-19 vaccine. Read more...

Serum News

30 July, 2021

CII to work with Serum Institute of India to expand vaccination across small towns and rural areas

The Confederation of Indian Industry (CII) has entered into an agreement with Serum Institute of India (SII) to accelerate vaccination in partnership with industry, including healthcare providers. The vaccine drive will target communities in India’s small towns and rural areas to ensure wide coverage. Read more...

Serum News

30 June, 2021

India Global Forum: Global Health - Delivering Radical Outcomes

In conversation with Adar Poonawalla, CEO, Serum Institute of India.

View

Serum News

15 February, 2021

World Health Organisation (WHO) grants Emergency Use Listing (EUL) for the AstraZeneca/Oxford COVID-19 vaccine manufactured by Serum Institute of India

World Health Organisation (WHO) grants Emergency Use Listing (EUL) to the AstraZeneca/Oxford COVID-19 vaccine 'COVISHIELD' ChAdOx1-S [recombinant] manufactured by Serum Institute of India (SII). AstraZeneca and SII will now work with the COVAX initiative, enabling equitable global access to its COVID-19 vaccines.Read more...

Serum News

08 February, 2021

UK Secretary of State for International Trade, Liz Truss visits Serum Institute of India

UK delegation led by Secretary of State for International Trade Liz Truss visited the Serum Institute of India. Read more...

Serum News

04 February, 2021

CEO of Serum Institute of India, Adar Poonawalla in conversation with CNN's Julia Chatterley

Serum Institute of India's CEO Adar Poonawalla discusses the need for global harmonization of regulation and vaccine licensing with CNN's Julia Chatterley. View

Serum News

04 February, 2021

Dynavax and Serum Institute of India Announce First Participant Dosed in a Phase 1 Clinical Trial Evaluating an Improved Tdap Vaccine Adjuvanted with CpG 1018

Dynavax and Serum Institute of India are collaborating to develop an adjuvanted tetanus, diphtheria, and acellular pertussis (Tdap) booster vaccine candidate adjuvanted with CpG 1018. Read more...

Serum News

03 February, 2021

COVAX concludes long-term supply agreement with the Serum Institute of India for covid-19 vaccines

UNICEF Executive Director Henrietta Fore stated at briefing on COVAX publishing interim distribution forecast, the conclusion of a long-term supply agreement with the Serum Institute of India for covid-19 vaccines, to access two vaccine products through technology transfer from ASTRAZENECA and NOVAVAX. Read more...

Serum News

01 February, 2021

Dr. Cyrus Poonawalla calls on Vice President of India, Shri M. Venkaiah Naidu

Dr. Cyrus Poonawalla Chairman and Managing Director of Serum Institute of India accompanied by the company's Executive Director Natasha Poonawalla called on Vice President of India, Shri M. Venkaiah Naidu at Upa-Rashtrapati Nivas, New Delhi and apprised him about the progress made by the Serum Institute. Read more...

Serum News

25 January, 2021

Mission 'Vaccine Maitri' by Government Of India

As part of its Mission 'Vaccine Maitri', Government of India begins supplying Serum Institute of India's COVISHIELD vaccine to neighbouring and key partner countries. Read more...

Serum News

15 January, 2021 - NDTV

Inside Serum Institute - India's Covid Vaccine Hub: NDTV

NDTV takes you inside Serum Institute of India where the COVISHIELD vaccine is being manufactured.View

Serum News

12 January, 2021 - Serum Institute Of India

An emotional moment for the team at @SerumInstIndia

'An emotional moment for the team at @SerumInstIndia as the first shipments of COVISHIELD finally leave for multiple locations across India', tweets SII CEO Adar Poonawalla. Read more...

Serum News

03 January, 2021

Drugs Controller General of India (DCGI) approves 'COVISHIELD' ChAdOx1-S (Recombinant) COVID-19 vaccine for restricted use in emergency situation

COVISHIELD ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant) manufactured by the Serum Institute of India has been approved for restricted use in emergency sitation by the Drugs Controller General of India (DCGI). Read more...

Serum News

30 December, 2020 - India Today TV

India Today TV's Rahul Kanwal visits Serum Institute of India's COVISHIELD vaccine production facility.

India Today TV's Rahul Kanwal visited the Serum Institute of India for a tour of the COVISHIELD vaccine production facility and speaks to CEO Adar Poonawalla about the vaccine. View...

Serum News

28 December, 2020 - Press Release

Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'

Serum Institute of India, announces the launch of India’s first indigenously developed pneumococcal vaccine – PNEUMOSIL; in the presence of Dr. Harsh Vardhan, Minister of Health and Family Welfare today. Read more...

Serum News

23 December, 2020

Serum Institute Of India And Dynavax Announce First Participants Dosed In The Phase 1/2 Clinical Trial For A COVID-19 Vaccine

Serum Institute of India (SIIPL) has partnered with Dynavax Technologies Corporation a biopharmaceutical company focused on developing and commercializing novel vaccines, and today jointly announced that the first participants have been dosed in the Phase 1 part of the Phase 1/2 clinical trial evaluating SIIPL's vaccine candidate adjuvanted with CpG 1018 to prevent COVID-19. Read more...

Serum News

14 December, 2020 - Press Release

Codagenix and Serum Institute of India Announce Commencement of First-in-Human Trial of COVI-VAC, A Single Dose, Intranasal Live Attenuated Vaccine for COVID-19

Codagenix, Inc., and the Serum Institute of India Pvt. Ltd. (SIIPL) today announced that a Phase 1 clinical trial of COVI-VAC received regulatory approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) and has commenced in London, UK. Read more...

Serum News

07 December, 2020 - PTI News

Serum Institute applies for emergency use authorisation for COVID-19 vaccine

Vaccine manufacturing major Serum Institute of India (SII) on Monday said it has applied to Drugs Controller General of India (DCGI) for emergency use authorisation for its COVID-19 vaccine Covishield. Read more...

Serum News

28 November, 2020, Serum Institute of India

Serum Institute Of India : Press Conference

Serum Institute of India Press Conference :7 PM : 28 November 2020.

SII CEO Adar Poonawalla briefs the media.Watch...

Serum News

28 November, 2020 - Serum Institute of India, Pune.

Hon'ble Prime Minister Shri. Narendra Modi visits Serum Institute of India

Hon'ble Prime Minister Shri. Narendra Modi visited the Serum Institute of India to review the Covid-19 vaccine development and met with SII Chairman & Managing Director Dr. Cyrus Poonawalla and CEO Mr. Adar Poonawalla. Read more...

Serum News

11 November, 2020 - Press Release

COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India

Serum Institute of India (SII) and Indian Council of Medical Research (ICMR)announce completion of enrolment of phase 3 clinical trials for COVISHIELD in India. ICMR and SII have further collaborated for clinical development COVOVAX (Novavax) developed by Novavax, USA and upscaled by SII. Read more...

Serum News

28 October, 2020, NDTV

Adar Poonawalla speaks to NDTV about the coronavirus vaccine.

Adar Poonawalla, CEO of Serum Institute of India in an exclusive interview with NDTV's Vishnu Som. View Interview...

Serum News

22 October, 2020

IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access

PUNE, INDIA, and NEW YORK — OCTOBER 22, 2020 — Today, IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, and Serum Institute of India Pvt. Ltd., a leading manufacturer of vaccines and biologics, announced an agreement with Merck, a leading science and technology company Read more...

Serum News

29 September, 2020

Serum Institute of India to produce up to an additional 100 million Covid-19 vaccine doses for India and low-and middle-income countries in 2021.

A further collaboration amongst the Serum Institute of India (SII), the world’s largest vaccine manufacturer by volume, Gavi and the Bill & Melinda Gates Foundation will accelerate the manufacture & delivery of up to 100 million doses of safe & effective COVID-19 vaccines for India & low-and middle-income countries (LMICs) as part of the Gavi COVAX AMC. Read more...

Serum News

22 September, 2020

Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer in conversation with CNN's Julia Chatterley..

Adar Poonawalla explains the timing, challenges & cost of vaccinating the world against covid19. Part 1.View Part 1...

Serum News

22 September, 2020

Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer in conversation with CNN's Julia Chatterley..

Adar Poonawalla explains the timing, challenges & cost of vaccinating the world against covid19. Part 2.View Part 2...

Serum News

22 September, 2020

Serum Institute of India begins manufacture of Codagenix's nasal COVID-19 vaccine candidate.

Serum Institute has received necessary regulatory approval from the Review Committee on Genetic Manipulation (RCGM) of India's Department of Biotechnology (DBT) for manufacturing Codagenix's COVID-19 vaccine candidate.Read more...

Serum News

17 September, 2020

Vaccine Access in the Era of COVID 19: Co-hosted by Johns Hopkins India Institute.

Ellen J. MacKenzie, Dean of the Bloomberg School of Public Health and Bloomberg Distinguished Professor in conversation with Dr. Cyrus Poonawalla, Chairman and Managing Director of the Serum Institute of India (SII).View...

Serum News

16 September, 2020

Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India.

Novavax, Inc. announced an amendment to its existing agreement with Serum Institute of India Private Limited (SIIPL) under which SIIPL will also manufacture the antigen component of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to over two billion doses annually, when all planned capacity has been brought online by mid-2021. Read more...

Serum News

16 September, 2020

Serum Institute of India gets DCGI nod to resume clinical trial of Oxford Covid-19 vaccine

Drugs Controller General of India (DCGI) on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford Covid-19 vaccine candidate in the country. Read more...

Serum News

12 September, 2020

Oxford COVID-19 vaccine: Serum Institute to resume trial in India after DCGI's nod

After Astrazeneca resumed Oxford University coronavirus vaccine trial in the United Kingdom, Serum Institute of India said that they will restart the trial in the country once the apex drug regulator allows. Read more...

Serum News

12 September, 2020

University of Oxford resumes vaccine trial

The ongoing randomised controlled clinical trials of the Oxford coronavirus vaccine ChAdOx1 nCoV-19 will resume across all UK clinical trial sites. Read more...

Serum News

08 September, 2020

SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19

SpyBiotech has signed an exclusive global licensing agreement with Serum Institute of India for the development of a novel virus-like-particle (VLP) vaccine targeting COVID-19. Read more...

Serum News

19 August, 2020

Serum Institute initiates phase 2, 3 clinical study on 1,600 volunteers for potential COVID-19 vaccine

Serum Institute of India has initiated the phase 2, 3 clinical trials to evaluate the safety and immune response of coronavirus vaccine candidate on healthy Indian adults after the company got approval from Drugs Controller General of India (DCGI) earlier this month. Read more...

Serum News

17 August, 2020

Bloomberg School of Public Health awards highest honor to Dr. Cyrus Poonawalla

The Johns Hopkins Bloomberg School of Public Health announce's Dean’s Medal recipients and has named Cyrus S. Poonawalla for his lifelong work in developing and delivering affordable vaccines. Read more...

Serum News

11 August, 2020

The World’s Best Hope for Enough Covid-19 Vaccine Comes from India

The Serum Institute of India is preparing to crank out a billion doses. And that's just the beginning.Read more...

Serum News

07 August, 2020

Gates Foundation Teams Up With Vaccine Maker to Produce $3 Covid-19 Shots

The Bill & Melinda Gates Foundation said it is backing the world’s largest vaccine maker, Serum Institute of India, to churn out 100 million doses of coronavirus vaccine for poorer countries and price them at less than $3.Read more...

Serum News

07 August, 2020

Serum Institute of India to produce up to 100 million Covid-19 vaccine doses for India and low- and middle-income Countries as early as 2021

Landmark collaboration between the Serum Institute of India (SII), Gavi, and Bill & Melinda Gates Foundation to produce up to 100 million Covid-19 vaccine doses for India and low and middle income Countries as early as 2021 Read more...

Serum News

06 August, 2020

Novavax signs COVID-19 vaccine supply deal with India’s Serum Institute

On Tuesday, Novavax reported that its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus in a small Read more...

Serum News

01 August, 2020

Serum Institute of India gets approval to start human trials for Oxford vaccine

Earlier this week, a committee of experts had deferred a decision on the request of SII to start trials and asked the company to amend its protocol for the clinical study Read more...

Serum News

27 July, 2020

Serum Institute conducting phase III clinical trial of BCG vaccine: DBT

About 6,000 health workers and high-risk individuals including those in close contact of COVID-19 patients have been enrolled in a clinical trial to determine Read more...

Serum News

23 July, 2020

Julia Chatterley In Conversation with CEO Mr. Adar Poonawalla

The Serum Institute Of India is the world largest vaccine maker and is currently partnering on a global mission to make COVID 19 vaccines available for all View...

Serum News

21 July, 2020, India Today Tv

Oxford Vaccine Raises Hope: When Will First Covid-19 Vaccine Be Available?

India Today TV's Rahul Kanwal in conversation with Adar Poonawalla CEO of Serum Institute & Prof. Andrew J. Pollard - Chief investigator and lead researcher of the Oxford vaccine trial. View Interview...

Serum News

21 July, 2020, CNN News18

Serum Institute, CEO, Adar Poonawalla On What Oxford's COVID-19 Vaccine Trials Mean To India

Serum Institute, CEO, Adar Poonawalla speaks to Zakka Jacob on the Oxford Vaccine trails success, third phase of tials in India, and what this means for the world's hopes for a COVID-19 vaccine by 2020 Watch...

Serum News

21 July, 2020 - ET Online

AstraZeneca vaccine's success in early human trials bodes well for Adar Poonawalla and Serum Institute

Adar Poonawalla's Serum Institute of India is one of Astra Zeneca's partners in the search for the vaccine and will potentially be responsible for the mass manufacture of the final product. Read more

Serum News

20 July, 2020 - LiveMint

Oxford COVID-19 vaccine early trial shows positive result, India to start trial next month

Oxford's vaccine is designed to reduce disease and transmission. The potential vaccine is already in large-scale phase III human trials Read more

Serum News

18 July, 2020 - TheIndianExpress.com

Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’

Serum Institute CEO Adar Poonawalla speaks to The Indian Express about their efforts to develop Covid-19 vaccines Read more

Serum News

15 July, 2020 - LiveMint

Serum Institute’s indigenous pneumonia vaccine gets DCGI approval

The Drug Controller General of India has approved Serum Institute of India Pvt Ltd’s indigenous pneumococcal polysaccharide conjugate vaccine, making it the first indigenously developed vaccine against pneumonia, the government said in a statement. Read more

Serum News

08 July, 2020 - expresspharma.in

Serum Institute of India expects COVID vaccine by year-end

Vaccine maker Serum Institute of India (SII) is hoping to develop a COVID-19 vaccine by the year-end as it is focusing on a “good and safe” product. Read more

Serum News

17 June, 2020 - LiveMint

Serum Institute of India to supply pneumonia vaccine to low-income nations

Pneumonia is the biggest single killer of children, claiming the life of a child every 39 seconds Read more

Serum News

10 June, 2020 - ET HealthWorld

Serum Institute investing USD 100 million on potential COVID-19 vaccine

Our manufacturing facility is ready and we plan to start production in two months. We are spending more than USD 100 million for this facility Read more

Serum News

04 June, 2020 - ForbesIndia

Adar Poonawalla's vaccine: No shot in the dark

Poonawalla is betting big on a Covid-19 vaccine, and preparing for the next possible pandemic Read more

Serum News

04 June, 2020 - Gavi

Global Vaccine Summit 2020

World leaders make historic commitments to provide equal access to vaccines for all Read more

Serum News

05 June, 2020, GAVI - Global Vaccine Summit 2020 - London

World leaders make historic commitments to provide equal access to vaccines for all

The Global Vaccine Summit, hosted by the UK, raises US$ 8.8 billion from 32 donor governments and 12 foundations, corporations and organisations to immunise 300 million children and support the global fight against COVID-19. Read more - GAVI.org

Serum News

05 June, 2020, Oxford University - News

Oxford University’s COVID-19 vaccine: next steps towards broad and equitable global access

The University of Oxford in partnership with AstraZeneca has taken the next steps in its commitment to broad and equitable global access to Oxford’s COVID-19 vaccine, following landmark agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India (SII). Read more - Oxford University

Serum News

05 June, 2020, MoneyControl.com

How Serum Institute became the Jio of coronavirus vaccine deals

AstraZeneca is the latest deal that Pune-based Serum Institute has stitched together. How did the 50-year-old vaccine maker become the face of the Indian fight against COVID-19? Read more - MoneyControl.com

Serum News

04 June, 2020, British High Commission - GOV.UK

India joins UK’s global vaccine mission

The UK organised the Global Vaccine Summit 2020 on 4 June, helping secure US$7.4 billion (approximately £6 billion) in funding to support global vaccine supply and immunisation. Read more - gov.uk

Serum News

04 June, 2020, AstraZenca.com

Agreements with CEPI and Gavi and the Serum Institute of India will bring vaccine to low-and-middle income countries and beyond

AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s potential COVID-19 vaccine, AZD1222, following landmark agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India (SII). Read more - AstraZenca

Serum News

03 June, 2020, GAVI.org

HPV vaccine manufacturers commit to provide enough supply to immunise at least 84 million girls in Gavi countries

On the eve of the Global Vaccine Summit 2020, Serum Institut of India commits to increasing and prioritising HPV vaccine supply to Gavi-supported countries, which have among the highest cervical cancer burdens in the world. Read more - GAVI.org

Serum News

23 May, 2020, Republic World - Live Tv

Serum Institute Of India Begins 3rd Phase Clinical Trials Of Recombinant-BCG Vaccine On Patients

In a massive development, a vaccine developed by Pune's Serum Institute of India (SII) is currently being tested at several Pune hospitals like - Ruby Hall, KEM Pune, Jehangir Hospital. Serum is carrying out phase 3 clinical trials of the Recombinant-BCG vaccine in 30 locations across the nation. Read more - Republic World - Live Tv

Serum News

23 May, 2020, Reuters

How one Indian company could be world's door to a Covid-19 vaccine

If the world is to gain access to a vaccine for COVID-19, there’s a good chance it will pass through the doors of Serum Institute of India. Read more -Reuters

Serum News

22 May, 2020, ThePrint

Ignore hype and euphoria over any Covid vaccine news for next 2-3 months: Adar Poonawalla

At ThePrint's Off The Cuff, Serum Institute of India CEO Adar Poonawalla said efficacy and yields of production can be established only after Phase 3 trials. Read more -ThePrint

Serum News

22 May, 2020, ThePrint

Off The Cuff with Adar Poonawalla

ThePrint's Editor-in-Chief Shekhar Gupta in conversation with Adar Poonawalla, CEO & Owner of Serum Institute of India. View Interview...

Serum News

21 May, 2020, Gulf News

Your COVID-19 vaccine: $13.20 per shot planned by Indian biotech firm

Serum Institute of India (SII), the world's largest maker of vaccines by volume, envisages a price of Rs. 1,000 ($13.20) per vaccine - but governments would give it to people with charge, Said SII's Dr. Cyrus Poonawalla. Read more -Gulf News

Serum News

18 May, 2020, DW

Coronavirus vaccine: India could play decisive role in distribution

The Serum Institute of India (SII) is ramping up production of the Oxford vaccine candidate in anticipation of it passing trials. DW spoke with Serum's CEO Adar Poonawalla about when a vaccine could be ready. Read more -DW

Serum News

28 April, 2020, NDTV

COVID-19 Vaccine Likely By September

Adar Poonawalla tells NDTV, Serum Institute of India will start producing the vaccine in May, which should be ready when the Oxford trials end. Watch the interview with Nidhi Razdan - NDTV

Serum News

24 April, 2020, CNBC-TV18

Adar Poonawalla discusses Serum Institute of India's partnership with the University of Oxford vaccine project with Shereen Bhan, CNBC-TV18

WHO released a report stating as of April 11th, there are over 70 vaccine candidates are in various stages of trial. UK already started human trials with India's Serum Institute as partner. Watch this CNBC-TV18 special.

Serum News

22 April, 2020, - India Today

Serum Institute has partnered with the University of Oxford vaccine project as one of the 7 global institutions behind manufacturing the vaccine to combat Covid-19

A team of scientists at the University of Oxford are working to produce a vaccine to combat Covid-19. Adar Poonawala's Serum Institute has partnered with the Oxford vaccine project as one of the 7 global institutions behind manufacturing the vaccine. More at: India Today

Serum News

16 April, 2020, - Maharashtra Times - Marathi

Serum News

15 April, 2020, - Maharashtra Times - Marathi

Serum News

07 April, 2020, - Fortune India

Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla

With Indian authorities expediting approvals, a viable Coronavirus vaccine may be commercially available earlier than anticipated. India may get a viable Covid-19 vaccine by the second quarter of 2022, ahead of the original estimated timeline of late 2022, says Adar Poonawalla, chief executive officer of Serum Institute of India (SII). Read more at: Fortune India

Serum News

02 April, 2020, - CNBC-TV18

Serum Institute to go for human trials for COVID-19 vaccine by year-end, says Adar Poonawalla

Adar Poonawala, CEO of Serum Institute of India, said, “It does take 6-7 years normally to make a vaccine. However, I think we should be able to go into human trials by the end of this year because we are entering into animal studies in about 3 weeks from today. So, that is very encouraging news and I can revise my earlier estimate from 2022 to maybe early next year. Read more at: CNBC-TV18

Serum News

02 April, 2020, - Economic Times - Health World

Mylab partners with SII’s Poonawalla, APG’s Pawar to scale-up production of Covid-19 test kits

Mylab Discovery Solutions Pvt Ltd has partnered with Serum Institute of India’s CEO Adar Poonawalla and Abhijit Pawar, Chairman of APG to scale up the operations of Covid-19 testing kits. Read more at: Economic Times - Health World

Serum News

01 April, 2020

Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18

Serum Institute of India has partnered with American biotechnology firm Codagenixto develop a vaccine against COVID-19, and expects it to be ready by early 2022. View Interview: CNBC-TV18 News

Serum News

17 March, 2020

Serum Institute’s Journey To Success | ET NOW

Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. View Video...

Serum News

19 February, 2020, - The Economic Times

Serum Institute to be ready with coronavirus vaccine by 2022

Serum Institute of India (SII) expects to be ready with a vaccine against the novel coronavirus (COVID-19) by early 2022. The vaccine candidate, developed by SII in partnership with American biotechnology firm Codagenix, has progressed to the pre-clinical test phase and we hope to be ready with the vaccine by early 2022," SII CEO Adar Poonawalla said. . Read more at: economictimes.indiatimes.com

Serum News

20 January, 2020

India first responder to fight emergency health crisis in Maldives

Ministry of External Affairs, Govt. of India, working closely with Ministry of Health procured a supply of 30,000 doses of Measles/Rubella Vaccines from the Serum Institute of India in respose to a emergency health crisis in the Maldives. Read more at: economictimes.indiatimes.com

Serum News

20 December, 2019

A new pneumococcal vaccine is here! Why this matters

With a recent approval from the World Health Organization, this high-quality, more affordable vaccine is poised to help more countries access protection against the top cause of deadly childhood pneumonia.more...

Serum News

20 December, 2019, REFORMA - Mexico [spanish]

Affordable Indian pneumococcal vaccine

The World Health Organization (WHO) certified the first pneumococcal vaccine produced by a manufacturer from a developing country, India.The production of a third pneumococcal conjugate vaccine (PCV), manufactured by the Serum Institute of India, will make it possible to extend immunization against the disease that causes greater infant mortality worldwide.more...

Serum News

20 December, 2019, Express Healthcare - Indian Express Newspaper

Serum Institute of India develops affordable pneumonia vaccine

This milestone marks a key step toward improving pneumococcal conjugate vaccine affordability and enabling sustainable access for low- and middle-income countries. Read more at: expresshealthcare.in

Serum News

19, December, 2019

New pneumococcal vaccine from Serum Institute of India achieves WHO prequalification

This milestone marks a key step toward improving pneumococcal conjugate vaccine affordability and enabling sustainable access for low- and middle-income countries.more...

Serum News

17 November, 2019

Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla

Dr. Cyrus Poonawalla was conferred with the Indian Council of Medical Research (ICMR) 'Lifetime Achievement Medal' for his outstanding contribution in healthcare by Bill Gates at the headquarters of ICMR in New Delhi.more...

Serum News

06 November, 2019

Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum

Dr. Cyrus Poonawalla was conferred with the 'Lifetime Achievement Award’ by the Asian Business Leadership Forum (ABLF) at the awards ceremony held on 6th November 2019 in Dubai.more...

Serum News

09 September, 2019

Serum Institute of India's new plant inaugurated by Hon’ble Union Health Minister Dr. Harsh Vardhan

Serum Institute of India's new plant inaugurated by Hon'ble Union Health Minister Dr. Harsh Vardhan.more...

Serum News

26 June, 2019

Dr. Cyrus & Mr. Adar Poonawalla - Exclusive Interview With Rahul Kanwal - Jab We Met.

Dr. Cyrus Poonawalla & Mr. Adar Poonawalla interviewed by Rahul Kanwal for India Today's Jab We Met TV Program. View Video...

Serum News

26 June, 2019

Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.

Dr. Cyrus Poonawalla was conferred with the prestigious 'Degree of Doctor of Science, honoris causa' by the University of Oxford, U.K. at a glittering ceremony on June 26, 2019. more...

Serum News

26 June, 2019

Dr. Cyrus Poonawalla being conferred with Honorary Degree from Oxford University.

Dr. Cyrus Poonawalla being conferred with the 'Degree of Doctor of Science, honoris causa' by the University of Oxford, U.K. held on June 26, 2019. View Video...

Serum News

10 December, 2018

Dr. Cyrus Poonawalla wins inaugural "VACCINE HERO" AWARD' by Gavi.

Dr. Cyrus Poonawalla, was given the first ever Vaccine Hero award by Gavi, the Vaccine Alliance at Gavi's mid-term review in Abu Dhabi. View Video...

Serum News

10 December, 2018

SERUM FOUNDER WINS INAUGURAL "VACCINE HERO" AWARD

Dr Cyrus Poonawalla, Founder of Serum Institute of India (SII) and Chairman of Poonawalla Group, has been given the first ever Vaccine Hero award by Gavi, the Vaccine Alliance. more...

Serum News

3 June, 2018

Dr. Cyrus Poonawalla conferred 'Doctor of Humane Letters' by The University of Massachusetts Medical School

The University of Massachusetts Medical School conferred an honorary degree of 'Doctor of Humane Letters' to Dr. Cyrus Poonawalla at the 45th Commencement Activities held in Worcester, U.S.A on June 3rd 2018 more...

Video

June, 2018

University of Massachusetts Medical School honors Dr. Cyrus Poonawalla

The University of Massachusetts Medical School to confer honorary degree to Dr. Cyrus Poonawalla at their 45th Commencement Activities

Serum News

January, 2018

Mr. Adar Poonawalla conferred D.Litt degree by Ajeenkya D Y Patil University

Conferment of Honorary Degree of Doctor of Letters (D.Litt) to Mr. Adar Poonawalla, CEO of Serum Institute of India by Ajeenkya D Y Patil University more...

Serum News

November, 2017

Adar Poonawalla is Indian of the Year in CSR Business Category | CNN-News18

Adar Poonawalla, CEO of Serum Institute received the Outsatanding achievement in Business & CSR from CNN-News18's Indian of the Year Awards 2018 more...

Rotasiil Launch

31 October, 2017

Serum Institute of India launches Two New Vaccines - Rotasiil & Rabishield

Serum Institute of India has launched two new products - Rotasiil and Rabishield for rotavirus causing diarrhoea and rabies respectively.more...

news november

Sunday, November 13, 2016

Prime Minister Narendra Modi visits
Serum Institute of India

Hon'ble Prime Minister Shri. Narendra Modi visited the Serum Institute of India on Sunday 13th November and met with the Chairman & Managing Director Dr. Cyrus Poonawalla and CEO Mr. Adar Poonawalla. more...

news november

Wednesday, March 04, 2015

Governor confers Honorary D Litt to
Dr. Cyrus Poonawalla

Hon'ble Governor of Maharashtra and Chancellor of Universities in the State, Ch Vidyasagar Rao, conferred the Honorary D Litt (Honoris Causa) on Dr. Cyrus Poonawalla for his contributions to public health by manufacturing low cost vaccines. more...

news november

February 2015

Dr. Cyrus Poonawalla meets
Hon'ble Prime Minister, Shri. Narendra Modi

Hon'ble Prime Minister, Shri. Narendra Modi being explained by Dr. Cyrus Poonawalla of how Serum Institute of India has contributed worldwide by protecting more than 60% of all children born in 2014. more...

news november

Thursday, February 05, 2015

Dr. Cyrus Poonawalla named the Ernst & Young Entrepreneur of the Year 2014

Dr. Cyrus S. Poonawalla, Chairman and Managing Director, Serum Institute Of India, who pioneered the development of affordable life-saving vaccines and is counted among the largest vaccine manufacturers more...

news november

Wednesday, January 28, 2015

Dr. Cyrus Poonawalla receives the CHEMTECH "
Lifetime Achievement Award"

Dr. Cyrus Poonawalla was awarded the CHEMTECH "Lifetime Achievement Award" at the CHEMTECH PBW Leadership & Excellence Awards held on 28th January at Mumbai. more...

news november

Sunday, November 09, 2014

Dr. Cyrus Poonawalla awarded the Punyabhushan Award [Pride of Pune]

Dr. Cyrus Poonawalla was conferred with the 26th Punyabushan award [Pride of Pune] at the hands of Shri. Sharad Pawar and Shri. N. R. Narayana Murthy at Balgandharva Rangamandir, Pune on Sunday, 9th November 2014. more...

news november

Friday, April 04, 2014

Dr. Cyrus Poonawalla receives The Asian Award for the "Business Leader of the Year"

Dr. Cyrus Poonawalla was awarded The Asian Award for the "Business Leader of the Year" at Grosvenor House, London on 4th April 2014. more...

Tuesday, March 04, 2014

SERUM / BBIO - Inactivated Polio Vaccine (IPV) made available at affordable prices to the world’s children

Serum Institute of India and Bilthoven Biologicals B.V., The Netherlands, have endeavoured to support the Programme to reach the Global Polio Eradication Initiative [GPEI] Endgame Strategic Plan 2013-2018, by substantially reducing the price of IPV from the prevailing price available in the market, in the recent tender bid with UNICEF. more...

Friday, December 27, 2013

10th World Zoroastrian Congress, 2013

The 10th World Zoroastrian Congress held in Mumbai, India was sponsored by the Serum Institute of India and inaugurated by the President of India, Pranab Mukherjee along with Governor of Maharashtra K. Sankaranarayanan & Dr. Cyrus Poonawalla on 27th December 2013.

more...

news november

Sunday, November 10, 2013

Winning accolades from His Royal Highness Prince of Wales

His Royal Highness the Prince of Wales made a private visit to Serum Institute on 10th November 2013 as he was keen to know more about the manufacture of inexpensive yet high quality vaccines that saves the lives of millions of children across the globe. more...

news november

Sunday, November 10, 2013

At Serum Institute, HRH Prince of Wales takes an update on MMR vaccine

On their maiden visit to the city, Prince Charles and his wife Camilla Parker Bowles on Sunday made a special stopover at the Serum Institute of India. While the Prince of Wales interacted with scientists and senior officials at the manufacturing facility, plants globally, the Duchess of Cornwall paid a visit to the legendary Poonawalla stud farm. more...

Sunday, November 10, 2013

Nothing official about it

Dr. Cyrus Poonawalla & Adar Poonawalla gave His Royal Highness Prince of Wales a guided tour of the sprawling Serum Institute Facility.“I’m impressed,” Charles told a gaggle of the institute’s scientists, with whom he engaged in a long conversation. more...

Tuesday, October 29, 2013

Poonawallas to host Prince Charles.

The royal couple will be making a special stopover in Pune on November 10 as the personal guests of Cyrus and Adar Poonawalla.

more...

news november

Wednesday, July 4, 2012

Serum Institute of India Ltd. acquires Bilthoven Biologicals of Netherlands

Serum Institute of India Ltd. has acquired Bilthoven Biologicals of Netherlands. Through the acquisition, the Serum Institute will get access to technology and expertise for making the Injectable Polio Vaccine (Salk), a unique capability and expertise that is currently possessed by a mere three other vaccine manufacturing plants globally. more...

news november

Sunday, June 3, 2012 PuneMirror

Meeting minutes with Bill Gates

Charity has different faces, and the Microsoft founder wears one defined by humility, found the Poonawallas as they showed him around their vaccine manufacturing facility. more...

news november

Friday, June 1, 2012 The Indian Express

Bill Gates visits Serum Institute, meets vaccine hero Poonawalla

Bill Gates on Thursday visited the Serum Institute of India in Pune, met its CMD Dr. Cyrus Poonawalla whom he referred to as one of the seven vaccine heroes, and evinced interest in several products it is developing. more...

Wednesday, November 2, 2011 Forbes.com

Bill Gates lists Dr. Cyrus Poonawalla as one of seven Most Influential Vaccine Heroes

His Serum Institute, says Gates, “makes more vaccines than anybody,” including one for meningitis that sells for a mere 50 cents a dose. These pioneers in breakthrough research (and, in one case, manufacturing) are “fascinating, mythic guys,” says Gates. more...

Friday, August 5, 2011 Serum Institute of India Ltd., Pune

Serum & Merck Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conjugate Vaccine

Serum Institute of India Ltd. and Merck have entered into an agreement to develop and commercialize a pneumococcal conjugate vaccine (PCV) for use in the emerging and developing world countries of the world. more...

Monday, July 11, 2011 Press Information Bureau, Government of India

WHO lauds Serum Institute's efforts at BRICS meeting in China

WHO Director-General Dr. Margaret Chan singled out India's effort when she stated that when African countries wanted a meningococcal vaccine at a cost of not more than 50 cents, it was the Serum Institute of India which came forward and did the job. “All the major manufacturers of the world were approached by WHO but could not meet the cost criteria, which was critical for the African countries. The supply of this vaccine by India has saved hundreds and thousand of lives in low & middle income African countries, where a person contracting meningitis often means 4-5 months of a household's income” she said. more...

news november

Tuesday, June 14, 2011 Times of India

City's Serum Institute plays vital role in saving lives

Bill Gates & British Prime Minister David Cameron praise Dr. Cyrus Poonawalla & Serum Institute for cutting vaccine prices. Serum offered GAVI the pentavalent vaccine at $1.75 per dose. The vaccine was purchased by GAVI a couple of years ago at more than $3 per dose. more...

news november

Tuesday, June 14, 2011 Sakal Times

Serum's vaccine will be world's most affordable

Dr. Poonawalla makes far-reaching pledge to Global Alliance for Vaccines and Immunisation (GAVI) in London. Serum Institute has made a commitment to cut the price of its pentavalent vaccine by 60 % - the lowest possible cost in the world. more...

Tuesday, June 14, 2011 DNA

Pharma giants urged to lower vaccine prices

Serum Institute of India Ltd (SII), at an international meet in London, has appealed to big pharma companies and suppliers to follow the principle of ‘philanthropic pricing policy’ for the benefit of underprivileged children across the world.

Poonawalla announced that SII has offered GAVI its pentavalent vaccine at $1.75, which was earlier purchased by GAVI at more than $3 per dose. “This is the most affordable vaccine offered by any manufacturer in the world,” Poonawalla said more...

Monday, June 13, 2011 DNA

Serum Institute lowers price of pentavalent vaccine

The Bill and Melinda Gates Foundation has welcomed the initiative of city-based pharmaceutical giant, Serum Institute of India (SII), to lower the price of its pentavalent vaccine for the developing world and for the United Nations Children’s Fund (Unicef). more...

Monday, June 13, 2011 Indian Express

Offer vaccines at lower prices: Poonawalla to pharma giants

Dr Cyrus Poonawalla, chief managing director of Serum Institute of India, on Monday urged big pharmaceutical firms to take their lead and offer vaccines at lower prices for saving lives. He was speaking at a pledging conference in London held by the Global Alliance for Vaccines and Immunisation (GAVI). British Prime Minister David Cameron and Bill Gates, co-founder of the Bill and Melinda Gates foundation. more...

Monday, December 27, 2010

NDTV Profit TV Interview with Dr. Cyrus & Adar Poonawalla.

View Interview

Wednesday, September 29, 2010     Sakal Times

Dr. Cyrus Poonawalla receives US Excellence Award from PAHO & PAHEF

The Pan American Health Organization (PAHO) and the Pan American Health and Education Foundation (PAHEF) have presented Dr Cyrus S Poonawalla, with the Award for “Excellence in Inter-American Public Health”, making him the first Indian to get this prestigious honor in Washington DC, USA. Dr. Poonawalla received this award from Dr. Mirta Roses Periago, director of the Pan American Health Organization (PAHO) for his extraordinary contribution to eliminate rubella and congenital rubella syndrome in America. more...

Wednesday, September 29, 2010

Dr. Cyrus S. Poonawalla interview at the Pan American Health Organization about Rubella vaccines & Serum Institute of India.

View Interview

Thursday, July 15, 2010 BioSpectrum

Serum Institute launches intra-nasal swine flu vaccine Nasovac in India

Serum Institute of India launched its intra-nasal Swine Flu Vaccine View Interview

Friday, August 14, 2009 DNA Pune

Vaccine is Serum Institute's top priority

City-based Serum Institute of India has been told to concentrate on the development of the H1N1 vaccine and put the development of H5N1 (avian flu) vaccine on the back burner by the World Health Organisation (WHO). more...

Wednesday, August 5, 2009 DNA Mumbai

Serum Institute to speed up vaccine production

Serum Institute of India (SII) in Pune is looking forward to an early date for producing a H1N1 vaccine. more...

Monday, August 3 2009

The Forbes India Show, CNBC TV18 TV Interview

View Interview

Friday, July 31, 2009 Sakal Times Pune

Serum Institute preparing vaccine

Serum Institute is working on Influenza A H1N1 virus strain to prepare a injectable vaccine to be ready for animal testing in the next two months. more...